Johnson & Johnson equity report –J&J fundamentally underappreciated

This report was prepared by Gonçalo André and Tomás Branco, two Master in Finance students of Nova School of Business and Economics (“Nova SBE”), within the context of the Field Lab –Equity Research. The goal was to evaluate Johnson & Johnson’s intrinsic value. Therefore, a thorough analysis of...

Full description

Bibliographic Details
Main Author: Branco, Tomás De Andrade Guerra Fazenda (author)
Format: masterThesis
Language:eng
Published: 2021
Subjects:
J&J
Healthcare
Valuation
Undervalued
Drugs
Innovation
R&D
Patents
Regulation
Litigations
Oncology
Dcf
Sotp
Domínio/Área Científica::Ciências Sociais::Economia e Gestão
Online Access:http://hdl.handle.net/10362/115564
Country:Portugal
Oai:oai:run.unl.pt:10362/115564
Description
Summary:This report was prepared by Gonçalo André and Tomás Branco, two Master in Finance students of Nova School of Business and Economics (“Nova SBE”), within the context of the Field Lab –Equity Research. The goal was to evaluate Johnson & Johnson’s intrinsic value. Therefore, a thorough analysis of itsoperating segments and industries was conducted. Our valuation model resulted in a share price of $166.00, which led to the conclusion that J&J is trading below its fair value. In addition, it was measured how sensitive the model is to changes in its underlying assumptions and to J&J’s future operating results.

Similar Items